Feature

The Biology of ‘Precancer’: Stopping Cancer Before It Starts


 

The Precancer Push

Stanford’s findings add information to prior biomarkers and may provide a way to identify “bad-acting tumors” from a simple blood draw measuring germline epitope burden, Dr. Curtis said. Looking further ahead, “this also reveals a new source of epitopes that might be immunogenic and might be informative for the development of vaccines.”

Many labs are trying to understand the biology of precancer and exploring possible vaccines.

The National Cancer Institute’s Human Tumor Atlas Network is building three-dimensional models of the evolution from precancerous to advanced disease. And researchers at the Cancer Vaccine Institute at the University of Washington are developing a vaccine for a precancerous lesion linked to many ovarian cancers.

Dr. Domchek’s research explores whether breast cancers caused by mutations in the BRCA 1 and 2 genes can be intercepted at very early stages. In a clinical trial of healthy people with those mutations, Dr. Domchek and colleagues are attempting to “rev up the immune system to tackle telomerase,” an enzyme that’s over-expressed in 95% of cancers. The hope is for this experimental vaccine to lower their risk of developing cancer.

At the Fred Hutch Cancer Center, Seattle, Ming Yu, PhD, is studying how senescent cells affect immune cells in precancer. As cells age and stop dividing, she said, they can accumulate and create a “tumor-promoting microenvironment” in older people.

Dr. Yu has found that the antiaging drug rapamycin can eliminate those “zombie cells” in mice. She’s studying whether the “cleanup” can help prevent cancer and expects results in a few months.

In the years and decades to come, all of this could lead to a new era in cancer treatment.

“Most drug development starts with people with advanced cancer and then goes into the earlier and earlier spaces,” said Dr. Domchek. “But it may be that we’re thinking about it all wrong and that you really have to understand the unique biology of early lesions to go after them.”

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

False-Positive Mammography Results Linked to Reduced Rates of Future Screenings
MDedge Internal Medicine
Breast Cancer Hormone Therapy May Protect Against Dementia
MDedge Internal Medicine
High Breast Cancer Risk With Menopausal Hormone Therapy & Strong Family History
MDedge Internal Medicine
A Simple Blood Test May Predict Cancer Risk in T2D
MDedge Internal Medicine
Should Genetic Testing Be Routine for Breast Cancer?
MDedge Internal Medicine
Cancer Risk: Are Pesticides the New Smoking?
MDedge Internal Medicine
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
MDedge Internal Medicine
Black Women Have a Higher Risk for Death in BC Subtypes
MDedge Internal Medicine
Screening Identifies Familial Risk for Hereditary Breast and Ovarian Cancer in Large Health System
MDedge Internal Medicine
Popular Weight Loss Drugs Now for Patients With Cancer?
MDedge Internal Medicine